Georgetown University

1. Merck Sharp & Dohme Corporation $4,229,163 261 payments
2. Pfizer Inc. $3,371,411 182 payments
3. Ipsen Biopharmaceuticals, Inc $3,024,454 46 payments
4. Genentech, Inc. $2,791,737 275 payments
5. Eisai Inc. $2,297,239 137 payments
6. Daiichi Sankyo Inc. $2,020,382 41 payments
7. E.R. Squibb & Sons, L.L.C. $1,916,587 55 payments
8. Janssen Research & Development, LLC $1,360,512 167 payments
9. Boehringer Ingelheim Pharmaceuticals, Inc. $1,070,540 33 payments
10. AstraZeneca Pharmaceuticals LP $1,001,301 46 payments

1. U31402-A-U103 $2,020,382 41 payments
2. A Phase 1B2 Openlabel Study to Evaluate Safety Clinical Activity Pharmacokinetics and Pharmacodynamics of Avelumab Msb0010718c in Combination With Other Cancer Immunotherapies in Patients With Advanced Malignancies $1,653,552 22 payments
3. NAPOLI-2: Phase II Study of Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Previously Treated Advanced Biliary Tract Cancer $1,474,614 24 payments
4. A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease $1,379,414 57 payments
5. A Phase II, Single-arm, Multi-Center Study of Combination Pembrolizumab and Olaparib in the Treatment of Patients with Advanced Cholangiocarcinoma $1,365,310 5 payments
6. NAPOLI-2Phase II Study of Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Previously Treated Advanced Biliary Tract Cancer $794,016 9 payments
7. A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205 $680,084 2 payments
8. Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations $651,718 8 payments
9. Istradefylline effect on Parkinsons Disease Tremor, Motor symptoms and Non-motor symptoms $622,394 9 payments
10. KEYMAKER U01 Master Study A Phase 2 Umbrella Study with Rolling Arms of Investigational Agents with either Pembrolizumab in Combination with Chemotherapy or with Pembrolizumab Alone in Patients with Advanced Non-small Cell Lung Cancer NSCLC $563,421 4 payments

1. Patient care $459,886 33 payments
2. Other $100,010 8 payments
3. Professional salary support $57,470 23 payments
4. Overhead $22,170 5 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.